![](/fileadmin/_processed_/csm_dollars-499481_1280-_Gerd_Altmann_pixabay_55a91b9ae7.jpg)
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
![](/fileadmin/_processed_/csm_Neurosense-pipeline_38841e73e1.png)
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_Neuroblastom_Primary_super_close_merged_cfdf8283a7_47aac544fd.jpg)
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
![](/fileadmin/_processed_/csm_Elsie_e778d3c6d7.png)
GSK closes US$50m acquisition with Elsie Biotechnologies Inc
GlaxoSmithKline (GSK) plc has acquired Elsie Biotechnologies Inc, a San Diego-based biotechcompany dedicated to unlocking the potential of...
![](/fileadmin/_processed_/csm_Innocent_Meat_myo_satellete_muscle_cells_c_Innocent_Meat_0610a73033.png)
Innocent Meat bags €3m financing
The three-year-old startup announced it will use the new proceeds to optimise components of its automated plug-and-produce solution for mass...
![](/fileadmin/_processed_/csm_Decoy_cell_cytology_f1d4d78e91.png)
Memo Therapeutics AG increases Series C financing to CHF45m
New investors Ysios Capital and Kurma Partners joined existing Series C round investors including Pureos Bioventures, Swisscanto, Vesalius...